Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3666 | Sofosbuvir 400 MG plus Daclatasvir 200mg Wiki | 1.00 |
| drug2331 | MenACWY single dose Wiki | 1.00 |
| drug887 | ChAdOx1 nCoV-19 single dose Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine.
Description: COVID-19 virologically confirmed symptomatic cases (PCR positive).
Measure: Evaluate the efficacy of ChAdOx1 nCoV-19 vaccine against COVID-19 disease confirmed with PCR Time: 12 months post final vaccinationDescription: Occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination (in a subset of 200 participants)
Measure: Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination Time: 7 days post vaccinationDescription: Occurrence of serious adverse events
Measure: Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of serious adverse events Time: 12 months post final vaccinationDescription: Occurrence of episodes; intensified disease
Measure: Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of episodes; intensified disease Time: 12 months post final vaccinationDescription: Hospitalization for COVID-19 disease confirmed by PCR
Measure: Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: hospitalization for COVID-19 disease confirmed by PCR Time: 12 months post final vaccinationDescription: COVID-19 serious disease confirmed by PCR
Measure: Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: COVID-19 serious disease confirmed by PCR Time: 12 months post final vaccinationDescription: Death associated with COVID-19 disease
Measure: Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: death associated with COVID-19 disease Time: 6 monthsDescription: Antibodies against SARS-CoV-2 non-Spike protein (serum efficacy rates).
Measure: Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: antibodies against SARS-CoV-2 non-Spike protein (serum efficacy rates) Time: 12 months post final vaccinationDescription: Antibodies against the SARS-CoV-2 spike protein (serum conversion rates)
Measure: Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: antibodies against the SARS-CoV-2 spike protein (serum conversion rates) Time: 12 months post final vaccinationDescription: Virus neutralizing antibodies (NAb) against live and/or pseudotyped SARS-CoV-2 virus
Measure: Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: virus neutralizing antibodies (NAb) against live and/or pseudotyped SARS-CoV-2 virus Time: 12 months post final vaccinationDescription: Interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein
Measure: Assess the cellular immunogenicity of ChAdOx1 nCoV-19 candidate vaccine Time: 12 months post final vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports